Caidya is built to navigate modern clinical development, with the agility and global reach that make complex trials possible. We don’t sit across the table. We sit beside you, integrating and embedding patient-centric solutions to streamline your trials and help you bring novel treatments to the people who need them.
We’re agile, committed partners and proven experts, delivering clinical development strategies and services that reduce risk and help bring life-changing therapies to patients worldwide. From early foundations to key acquisitions and integration across regions, we’ve built a CRO designed for cross-border execution of complex clinical development programs.
$165M investment as Caidya embarks on the next phase of growth and transformation.
Caidya hires an experienced leader across the healthcare and life sciences sectors to lead its next phase of growth and innovation.
dMed-Clinipace rebrands as Caidya, with a united mission to liberate clinical research by sharing knowledge and delivering more personalized solutions.
dMed and Clinipace merge to accelerate cross-border trials and the delivery of innovative solutions to patients worldwide.
dMed acquires US-based Target Health as the first step toward delivering cross-border trial solutions.
dMed was founded by Dr. Lingshi Tan to deliver regulatory and clinical development service solutions in China.
Clinipace acquires full-service CRO Accovion, expanding its EU footprint.
Clinipace acquires Choice Pharma, a full-service CRO, to broaden its Asia-Pacific capabilities.
Clinipace acquires PFC Pharma Focus, a product development partner, to establish an EU presence.
Clinipace acquires Worldwide Clinical Research to accelerate global expansion.
Clinipace was founded by Jeff Williams and Chris Porter.
Real lives are more important than protocols. By prioritizing and understanding the patient journey, we design and execute trials that are practical, easy to participate in, and built for impact.
We are liberating clinical research through listening for understanding, thinking openly, owning the success of each project we conduct, and sharing our knowledge every step of the way.
Our purpose is simple: We help bring life-changing therapies to our global community through liberated clinical research.
Take Ownership
We treat each project like our own and take active responsibility for every deliverable to ensure the best client outcomes.
Radiate Passion
Our energy, passion, and courage is what sets us apart, going beyond the expected to make our projects succeed.
Share Knowledge
Sharing knowledge internally and with our partners ensures we make better decisions now and in the future.
Liberate Thinking
We trace every problem back to the root and enact changes or new processes to transform problems into solutions.
Join Forces
We celebrate our differences in background, culture, lifestyle, and skill knowing that together we are stronger.
CEO - Clinical-Stage Biopharmaceutical Company
Our commitment to quality, partnership, and execution of complex clinical trials is consistently recognized across the industry. From global clinical research excellence to client service and team performance, these awards reflect the strength of our people, our capabilities, and our focus on delivering meaningful results for our clients and their patients.
A CRO is a specialized partner that supports biopharma companies in designing, managing, and executing clinical trials. CROs provide services across the development lifecycle, from early phase strategy through global trial execution, data management, and regulatory support to help bring new therapies to market faster and with confidence.
Caidya is a global, full-service CRO offering end-to-end clinical development support, including study design, project management, clinical operations, clinical data management, biostatistics, regulatory support, and medical monitoring for local, regional, and international cross-border trials.
Caidya primarily partners with small to mid-sized biotech and biopharma innovators, acting as an extension of their teams to provide the expertise, flexibility, and global reach needed to advance complex clinical programs in areas including rare disease clinical research, oncology clinical research, and pediatric clinical research. Caidya also works with mid- to larger-sized pharma, providing FSP and hybrid delivery service models.
Caidya has deep expertise in complex therapeutic areas such as oncology, hematology, rare disease, cell and gene therapy, cardiovascular-metabolic, nephrology, and dermatology, with experience supporting trials from early-phase through global pivotal studies.
Caidya combines strategic insight, operational agility, and global infrastructure to streamline study design, improve patient recruitment, and enhance data quality—helping sponsors reduce timelines and make faster, more informed decisions. With long-standing operations in China, Caidya provides access to a growing and diverse patient population.